PUBLICATIONS

All publications

n=24, H index = 12, 8 first or corresponding author, 923 total cites (Google Scholar)

 

1.Fernández JJ, Marín A, Rosales R, Penrice-Randal R, Mlcochova P, Alvarez Y, et al. The IRE1α-XBP1 arm of the unfolded protein response is a host factor activated in SARS-CoV-2 infection. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870(5):167193.

2. Alrezaihi A, Penrice-Randal R, Dong X, Prince T, Randle N, Semple MG, et al. Enrichment of SARS-CoV-2 sequence from nasopharyngeal swabs whilst identifying the nasal microbiome. Journal of Clinical Virology. 2023:105620.

 3. De Neck S, Penrice-Randal R, Clark JJ, Sharma P, Bentley EG, Kirby A, et al. The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses [Internet]. 2023; 15(8).

4.   Goldswain H, Dong X, Penrice-Randal R*, Alruwaili M, Shawli GT, Prince T, et al. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection. Genome Biology. 2023;24(1):47.

5.   Donovan-Banfield Ia, Penrice-Randal R, Goldswain H, Rzeszutek AM, Pilgrim J, Bullock K, et al. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. Nature Communications. 2022;13(1):7284-.

6.   Penrice-Randal R*, Dong X, Shapanis A, Gardener AI, Harding N, Legebeke J, et al. Blood gene expression predicts intensive care unit admission in hospitalised patients with COVID-19. Frontiers in immunology. 2022.

7.   Penrice-Randal R*, Hartley C, Beliavskaia A, Dong X, Brandner-Garrod L, Whitten M, et al. New Cell Lines Derived from Laboratory Colony Triatoma infestans and Rhodnius prolixus, Vectors of Trypanosoma cruzi, Do Not Harbour Triatoma Virus. Insects. 2022;13(10):906.

8.   Russell CD, Valanciute A, Gachanja NN, Stephen J, Penrice-Randal R, Armstrong SD, et al. Tissue proteomic analysis identifies mechanisms and stages of immunopathology in fatal COVID-19. American journal of respiratory cell and molecular biology. 2022;66(2):196-205.

9.   Zhou J, Peacock TP, Brown JC, Goldhill DH, Elrefaey AME, Penrice-Randal R, et al. Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell reports. 2022;38(6):110344.

10.   Legebeke J, Lord J, Penrice-Randal R, Vallejo AF, Poole S, Brendish NJ, et al. Evaluating the immune response in treatment-naive hospitalised patients with influenza and COVID-19. Frontiers in Immunology. 2022:2163.

11.   Prince T, Dong X, Penrice-Randal R, Randle N, Hartley C, Goldswain H, et al. Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. Msphere. 2022:e00913-21.

12. Dong X, Penrice-Randal R, Goldswain H, Prince T, Randle N, Salguero FJ, et al. Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. GigaScience. 2022;11.

13. Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal R, et al. Tissue-specific immunopathology in fatal COVID-19. American journal of respiratory and critical care medicine. 2021;203(2):192-201.

14. Peacock TP, Penrice-Randal R, Hiscox JA, Barclay WS. SARS-CoV-2 one year on: evidence for ongoing viral adaptation. The Journal of general virology. 2021;102(4).

15. Aljabr W, Alruwaili M, Penrice-Randal R*, Alrezaihi A, Harrison AJ, Ryan Y, et al. Amplicon and metagenomic analysis of middle east respiratory syndrome (MERS) coronavirus and the microbiome in patients with severe MERS. Msphere. 2021;6(4):e00219-21.

16. Moore SC, Penrice-Randal R*, Alruwaili M, Randle N, Armstrong S, Hartley C, et al. Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode proteins involved in interferon antagonism. Viruses. 2020;12(10):1164.

Preprints

1. Penrice-Randal R, Strazzeri F, Ernst B, Eeckhout BV, Guiot J, Peired AJ, et al. Precision medicine for pandemics: stratification of COVID-19 molecular phenotypes defined by topological analysis of global blood gene expression. medRxiv. 2024:2024.04.15.24305820.

2. Penrice-Randal R, Bentley EG, Sharma P, Kirby A, Donovan-Banfield Ia, Kipar A, et al. The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in infected and immune suppressed mice. bioRxiv. 2024:2024.02.27.582110.

3. Xingna Z, Christopher PC, Christopher J, Michael H, Gary L, Claire S, et al. Can self-testing be enhanced to hasten safe return of healthcare workers in pandemics? Random order, open label trial using two manufacturers’ SARS-CoV-2 lateral flow devices concurrently. medRxiv. 2024:2024.04.04.24305332.

4. Clark JJ, Penrice-Randal R*, Sharma P, Kipar A, Dong X, Pennington SH, et al. Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. bioRxiv. 2021:2020-10. Submitted to Viruses

5. Prince T, Goldswain H, Penrice-Randal R, Turtle L, Fletcher T, Khoo S, et al. Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model. bioRxiv. 2021.

6. Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, et al. SARS-CoV-2 Omicron-B. 1.1. 529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. BioRxiv. 2021.

7. Cunningham-Oakes E, Pilgrim J, Darby AC, Appleton C, Jewell C, Rowlingson B, et al. Emerging variants of canine enteric coronavirus associated with seasonal outbreaks of severe canine gastroenteric disease. bioRxiv. 2022. Submitted to Emerging Infectious Diseases

​

E-book

1.   Bölke E, van Griensven, M., Schneider, E. M., Feldt, T., . Immune response to SARS-CoV-2 and implications for clinical outcome. Lausanne: Frontiers Media SA; 2023.